GT Biopharma, Inc. (GTBP) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -2.47M | -4.02M | -3.68M | -3.01M | -2.2M | -2.47M | -2.74M | -3.54M | -4.16M | -2.05M | -1.96M | -1.94M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -12.08% | -62.93% | -34.34% | 14.76% | 47.11% | -20.57% | -39.36% | -82.74% | -43.26% | 52.37% | 32.69% | 30.55% |
| Net Income | -2.83M | -5.71M | -3.11M | -1.43M | -776K | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46K | 432K | 379K | 7K | 3K | 8K | 0 | 120K | 102K | 433K | 547K | 398K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -11K | -383K | -232K | -1.04M | -126K | 1.24M | -93K | -93K | -630K | 106K | -463K | -303K |
| Working Capital Changes | 330K | 1.64M | -710K | -545K | -1.3M | 60K | 767K | 147K | -1.37M | 376K | 368K | -38K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 108K | 1.14M | -813K | -332K | -1.29M | 0 | 998K | 116K | -1.35M | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 1K | -1K | 7.86M | 5.03M | 478K | 1.84M | 2.66M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -2.82M | -1K | 7.86M | 0 | 478K | 1.84M | 0 |
| Cash from Financing | 4.58M | 8.3M | 977K | 5.88M | 616K | 0 | 0 | 2.98M | 0 | 0 | 0 | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 4.58M | 8.45M | 1.06M | 0 | 0 | 0 | 0 | 2.98M | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | -144K | -85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 5.88M | 616K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.11M | 4.28M | -2.7M | 2.86M | -1.59M | -2.47M | -2.74M | 7.3M | 871K | -1.57M | -119K | 722K |
| Free Cash Flow | -2.47M | -4.02M | -3.68M | -3.01M | -2.2M | -2.47M | -2.74M | -3.54M | -4.16M | -2.05M | -1.96M | -1.94M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -12.08% | -62.93% | -34.34% | 14.76% | 47.11% | -20.57% | -39.36% | -82.74% | -43.26% | 52.37% | 32.69% | 30.55% |
| FCF per Share | -0.08 | -0.73 | -0.93 | -1.09 | -0.94 | -1.30 | -1.23 | -2.07 | -3.01 | -1.48 | -1.44 | -1.45 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.17x | -0.44x | 0.10x | 2.84x | 0.65x | 0.80x | 0.95x | 1.84x | 0.69x | 0.81x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 213K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |